[The Short-Cycle Blinatumomab Therapy for MRD-Positive and Chemotherapy-Intolerant Pediatric ALL: Analysis of Short-Term Efficacy and Safety]
{{output}}
Objective: To evaluate the short-term efficacy and safety of a short-course blinatumomab regimen in children with acute lymphoblastic leukemia (ALL) who were minimal residual disease (MRD)-positive or chemotherapy-intolerant. ... ...
